Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749303 | 0.79 | GPR119 (0.41) | GPR119CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9936687 | 0.78 | GPR119 (0.41) | GPR119CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9936121 | 0.76 | GPR119 (0.47) | GPR119NPC1RAB9A | |
| SCHEMBL9936136 | 0.76 | GPR119 (0.56) | GPR119CHRM2L3MBTL3 | |
| SCHEMBL14749307 | 0.75 | CHRM2 (0.36) | GPR119CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2595915 | 0.72 | PNMT (0.36) | GPR119CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14616596 | 0.71 | GPR119 (0.43) | GPR119 | |
| SCHEMBL2595423 | 0.70 | GPR119 (0.66) | GPR119CHRM2 | |
| SCHEMBL14616597 | 0.69 | GPR119 (0.44) | GPR119 | |
| SCHEMBL14575532 | 0.69 | GPR119 (0.44) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729084-B2 | Benzofuranyl analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059858-A1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | GPR119 1/4885CHRM2 143/4885CHRM4 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.